PE20240588A1 - Terapias de combinacion - Google Patents
Terapias de combinacionInfo
- Publication number
- PE20240588A1 PE20240588A1 PE2023002970A PE2023002970A PE20240588A1 PE 20240588 A1 PE20240588 A1 PE 20240588A1 PE 2023002970 A PE2023002970 A PE 2023002970A PE 2023002970 A PE2023002970 A PE 2023002970A PE 20240588 A1 PE20240588 A1 PE 20240588A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- leukemia
- inhibitor
- menin
- combination
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title 1
- 208000032839 leukemia Diseases 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 101001109719 Homo sapiens Nucleophosmin Proteins 0.000 abstract 2
- 102100022678 Nucleophosmin Human genes 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- 229940123974 Cytidine deaminase inhibitor Drugs 0.000 abstract 1
- 229940083266 Dihydroorotate dehydrogenase inhibitor Drugs 0.000 abstract 1
- 102100030550 Menin Human genes 0.000 abstract 1
- 101710169972 Menin Proteins 0.000 abstract 1
- 239000003363 dihydroorotate dehydrogenase inhibitor Substances 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 208000018706 hematopoietic system disease Diseases 0.000 abstract 1
- 229940075628 hypomethylating agent Drugs 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000008707 rearrangement Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021093036 | 2021-05-11 | ||
| CN2021100523 | 2021-06-17 | ||
| CN2021100522 | 2021-06-17 | ||
| CN2022086004 | 2022-04-11 | ||
| CN2022086003 | 2022-04-11 | ||
| PCT/CN2022/091678 WO2022237719A1 (en) | 2021-05-11 | 2022-05-09 | Combination therapies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20240588A1 true PE20240588A1 (es) | 2024-03-21 |
Family
ID=81753153
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023002970A PE20240588A1 (es) | 2021-05-11 | 2022-05-09 | Terapias de combinacion |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20240261292A1 (https=) |
| EP (1) | EP4337215A1 (https=) |
| JP (1) | JP2024519322A (https=) |
| KR (1) | KR20240006638A (https=) |
| CN (2) | CN117337180A (https=) |
| AU (1) | AU2022271993A1 (https=) |
| CA (1) | CA3214861A1 (https=) |
| CL (2) | CL2023003330A1 (https=) |
| CO (1) | CO2023014325A2 (https=) |
| DO (1) | DOP2023000239A (https=) |
| IL (1) | IL308333A (https=) |
| MX (1) | MX2023013436A (https=) |
| PE (1) | PE20240588A1 (https=) |
| TW (1) | TW202308642A (https=) |
| UY (1) | UY39762A (https=) |
| WO (1) | WO2022237719A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202525813A (zh) | 2019-12-19 | 2025-07-01 | 比利時商健生藥品公司 | 經取代之直鏈螺環接衍生物 |
| EP4626426A1 (en) * | 2022-11-30 | 2025-10-08 | JANSSEN Pharmaceutica NV | Combinations comprising a menin-mll inhibitor and at least one other therapeutic agent |
| WO2024114666A1 (en) * | 2022-11-30 | 2024-06-06 | Janssen Pharmaceutica Nv | Combinations comprising a menin-mll inhibitor and a bcl-2 inhibitor |
| EP4698182A1 (en) * | 2023-04-17 | 2026-02-25 | Janssen Pharmaceutica NV | Combination of a menin-ll1 inhibitor, a dna intercalating agent and a pyrimidine analogue to treat a hematopoietic disorder |
| WO2025082444A2 (en) * | 2023-10-20 | 2025-04-24 | Janssen Pharmaceutica Nv | (r) -n-ethyl-5-fluoro-n-isopropyl-2- ( (5- (2- (6- ( (2-methoxyethyl) (methyl) amino) -2-methylhexan-3-yl) -2, 6-diazaspiro [3.4] octan-6-yl) -1, 2, 4-triazin-6-yl) oxy) benzamide, formulations and dosage regimens thereof, for use in treating cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TN2017000080A1 (en) | 2014-12-18 | 2018-07-04 | Takeda Pharmaceuticals Co | Solid state forms of fused heteroaromatic pyrrolidinones |
| WO2017214367A1 (en) * | 2016-06-10 | 2017-12-14 | Vitae Pharmaceuticals, Inc. | Inhibitors of the menin-mll interaction |
| WO2018175746A1 (en) * | 2017-03-24 | 2018-09-27 | Kura Oncology, Inc. | Methods for treating hematological malignancies and ewing's sarcoma |
| JP2022503792A (ja) * | 2018-09-26 | 2022-01-12 | クラ オンコロジー，インク． | メニン阻害剤を用いた血液悪性腫瘍の処置 |
| TW202104207A (zh) | 2019-04-17 | 2021-02-01 | 美商健生生物科技公司 | 二氫乳清酸脫氫酶抑制劑 |
| TW202525813A (zh) | 2019-12-19 | 2025-07-01 | 比利時商健生藥品公司 | 經取代之直鏈螺環接衍生物 |
-
2022
- 2022-05-09 PE PE2023002970A patent/PE20240588A1/es unknown
- 2022-05-09 AU AU2022271993A patent/AU2022271993A1/en active Pending
- 2022-05-09 MX MX2023013436A patent/MX2023013436A/es unknown
- 2022-05-09 CA CA3214861A patent/CA3214861A1/en active Pending
- 2022-05-09 JP JP2023568688A patent/JP2024519322A/ja active Pending
- 2022-05-09 US US18/560,233 patent/US20240261292A1/en active Pending
- 2022-05-09 CN CN202280034524.5A patent/CN117337180A/zh active Pending
- 2022-05-09 WO PCT/CN2022/091678 patent/WO2022237719A1/en not_active Ceased
- 2022-05-09 CN CN202410897503.7A patent/CN118845786A/zh active Pending
- 2022-05-09 KR KR1020237042472A patent/KR20240006638A/ko active Pending
- 2022-05-09 EP EP22725157.6A patent/EP4337215A1/en active Pending
- 2022-05-09 IL IL308333A patent/IL308333A/en unknown
- 2022-05-10 TW TW111117440A patent/TW202308642A/zh unknown
- 2022-05-11 UY UY0001039762A patent/UY39762A/es unknown
-
2023
- 2023-10-25 CO CONC2023/0014325A patent/CO2023014325A2/es unknown
- 2023-10-27 DO DO2023000239A patent/DOP2023000239A/es unknown
- 2023-11-08 CL CL2023003330A patent/CL2023003330A1/es unknown
-
2024
- 2024-09-26 CL CL2024002893A patent/CL2024002893A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2023003330A1 (es) | 2024-06-07 |
| JP2024519322A (ja) | 2024-05-10 |
| CN118845786A (zh) | 2024-10-29 |
| WO2022237719A1 (en) | 2022-11-17 |
| TW202308642A (zh) | 2023-03-01 |
| KR20240006638A (ko) | 2024-01-15 |
| IL308333A (en) | 2024-01-01 |
| CN117337180A (zh) | 2024-01-02 |
| DOP2023000239A (es) | 2024-04-30 |
| US20240261292A1 (en) | 2024-08-08 |
| CO2023014325A2 (es) | 2023-10-30 |
| EP4337215A1 (en) | 2024-03-20 |
| CA3214861A1 (en) | 2022-11-17 |
| AU2022271993A1 (en) | 2024-01-04 |
| UY39762A (es) | 2022-11-30 |
| CL2024002893A1 (es) | 2025-02-14 |
| MX2023013436A (es) | 2023-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20240588A1 (es) | Terapias de combinacion | |
| PE20240593A1 (es) | Terapias de combinacion | |
| BR112023020442A2 (pt) | Inibidor da protease 1 específica de ubiquitina (usp1) | |
| CL2022003733A1 (es) | Análogos de nucleósido de 1’-ciano y usos de los mismos | |
| UY37565A (es) | Agentes de iarn alfa-1 antitripsina (aat), composiciones que incluyen agentes de iarn aat y métodos de uso | |
| AR060609A1 (es) | Compuestos inhibidores de proteinquinasas c-fms. | |
| AR107828A1 (es) | 2-amino-n-[7-metoxi-2,3-dihidroimidazo-[1,2-c]quinazolin-5-il]pirimidin-5-carboxamidas como inhibidor de pi3k | |
| AR054347A1 (es) | Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion | |
| BR112018014661A2 (pt) | composição e composição para uso | |
| CL2021002217A1 (es) | Composición farmacéutica que comprende un inhibidor de flt3 y un agente hipometilante para tratar la leucemia mieloide aguda | |
| UY26564A1 (es) | Inhibidores del factor xa con aril - amidinas y sus derivados, y composiciones farmacéuticas que contienen los mismos | |
| AR127431A1 (es) | Compuestos novedosos | |
| DOP2022000107A (es) | Derivados de 1,2,4oxadiazol como agonistas del receptor hepático x | |
| UY39865A (es) | Pirazin-2-carboxamidas sustituidas como inhibidores de hpk1 para el tratamiento del cáncer | |
| AR125479A1 (es) | Inhibidores de il4i1 y métodos de uso | |
| PE20251702A1 (es) | Derivados de 2-amino-n-(4-amino-3,4-dioxo-1-(2-oxopirrolidin-3-il)butan-2- il)benzamida como inhibidores de proteasa para tratar o prevenir la infeccion por coronavirus | |
| AR065419A1 (es) | Metodo para inhibir la proliferacion de celulas tumorales | |
| AR111786A1 (es) | Composiciones de gemcabeno y su uso | |
| AR107935A1 (es) | Uso del compuesto 6-(4-(2,3-dimetilfenoxi)piperidin-1-il)metil)pirimidino-2,4(1h,3h)-diona o una sal farmacéuticamente aceptable del mismo para preparar un medicamento, combinación y composición farmacéutica que comprende dicho compuesto | |
| AR127783A1 (es) | Composición farmacéutica que comprende compuestos de drogas biofarmacéuticas | |
| MX2021003030A (es) | Composiciones farmaceuticas adecuadas para suministro articular y su uso en tratamiento de dolor de articulacion. | |
| AR038494A1 (es) | Composiciones de medicamentos sobre la base de agentes anticolinergicos y de agentes inhibidores de la cinasa del egfr | |
| AR126393A1 (es) | Terapia combinada para el tratamiento de enfermedades hepáticas | |
| AR041028A1 (es) | Profarmaco inhibidor de beta -lactamasa | |
| MX2022014295A (es) | Derivados de la bencilamina como inhibidores de los receptores del dominio de discoidina. |